24444-74-4

Upstream product

• 24444-75-5 4-hydroxydibenzothiophene 
• 77-78-1 dimethyl sulfate 
• 573721-33-2 6-methoxy-1,2,3,4-tetrahydro-dibenzothiophene 
• 74-88-4 methyl iodide 
• 132-65-0 dibenzothiophene 
• 92-52-4 biphenyl 
• 74128-84-0 2-bromo-1-iodo-3-methoxybenzene 
• 1993-03-9 o-fluorophenylboronic acid 
• 1264711-98-9 3-(2'-fluoro-3-methoxy-biphenyl-2-ylsulfanyl)propionic acid ethyl ester 
• 1264711-97-8 2-bromo-2'-fluoro-3-methoxybiphenyl 

Downstream Products

• 109404-17-3 4-methoxy-dibenzothiophene-5,5-dioxide 
• 118143-61-6 4-mercapto-6-hydroxydibenzothiophene 
• 881375-00-4 KU-0060648 
• 69747-61-1 1-chlorodibenzo[b,d]thiophen-4-ol 

Relevant academic research and scientific papers

1-substituted (dibenzo[ b,d ]thiophen-4-yl)-2-morpholino-4 h -chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity

Analogues of (dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one (NU7441), a potent inhibitor of DNA-dependent protein kinase (DNA-PK; IC 50 = 42 ± 2 nM), have been synthesized in which water-solubilizing groups [NHCO(CH2)nNR1R 2, where n = 1 or 2 and the moiety R1R2N was derived from a library of primary and secondary amines, e.g., morpholine] were placed at the 1-position. Several of the newly synthesized compounds exhibited high potency against DNA-PK and potentiated the cytotoxicity of ionizing radiation (IR) in vitro 10-fold or more (e.g., 2-(4-ethylpiperazin-1-yl)-N-(4- (2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thio-phen-1-yl)acetamide, 39; DNA-PK IC50 = 5.0 ± 1 nM, IR dose modification ratio = 13). Furthermore, 39 was shown to potentiate not only IR in vitro but also DNA-inducing cytotoxic anticancer agents, both in vitro and in vivo. Counter-screening against other members of the phosphatidylinositol 3-kinase (PI-3K) related kinase (PIKK) family unexpectedly revealed that some of the compounds were potent mixed DNA-PK and PI-3K inhibitors.

Green Preparation of Dibenzothiophene Derivatives Using 2-Biphenylyl Disulfides in the Presence of Molecular Iodine and Its Application to Dibenzoselenophene Synthesis

A protocol for the direct preparation of dibenzothiophenes from 2-biarylyl disulfides in the presence of an economic and ecological oxidant, molecular iodine, was explored. This protocol was used for the direct preparation of dibenzoselenophene.

INHIBITORS OF TRKA KINASE

The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof

Synthesis of functionalized dibenzothiophenes- An efficient three-step approach based on Pd-catalyzed C-C and C-S bond formations

A novel and efficient three-step protocol for synthesizing functionalized dibenzothiophenes (DBTs) from common starting materials and by using palladium-catalyzed carbon-carbon and carbon-sulfur bond formations is presented. The reaction conditions offer significantly improved functional-group tolerance and regioselectivity as compared to previously reported methods. A flexible and concise three-step protocol for the synthesis of functionalized dibenzothiophenes DBTs from readily available starting materials is presented. The method is based on two palladium-catalyzed reactions to prepare the masked thiophenols 4followed by deprotection and in situ cyclization to form the DBT skeleton. This approach offers improved functional-group tolerance as well as regiocontrol in the synthesis of functionalized DBTs as compared to previously reported methods.

DNA-dependent protein kinase (DNA-PK) inhibitors. synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype

Following the discovery of dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H- chromen-4-one (NU7441) (Leahy, J. J. J.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Richardson, C.; Rigoreau, L.; Smith, G. C. M. Bioorg. Med. Chem. Lett. 2004, 14, 6083-6087) as a potent inhibitor (IC50 = 30 nM) of DNA-dependent protein kinase (DNA-PK), we have investigated analogues in which the chromen-4-one core template has been replaced by aza-heterocyclic systems: 9-substituted 2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-ones and 8-substituted 2-morpholin-4-yl-1H-quinolin-4-ones. The 8- and 9-substituents were either dibenzothiophen-4-yl or dibenzofuran-4-yl, which were each further substituted at the 1-position with water-solubilizing groups [NHCO(CH 2)nNR1R2, where n = 1 or 2 and the moiety R1R2N was derived from a library of primary and secondary amines (e.g., morpholine)]. The inhibitors were synthesized by employing a multiple-parallel approach in which the two heterocyclic components were assembled by Suzuki-Miyaura cross-coupling. Potent DNA-PK inhibitory activity was generally observed across the compound series, with structure activity studies indicating that optimal potency resided in pyridopyrimidin-4- ones bearing a substituted dibenzothiophen-4-yl group. Several of the newly synthesized compounds (e.g., 2-morpholin-4-yl-N-[4-(2-morpholin-4-yl-4-oxo-4H- pyrido[1,2-a]pyrimidin-9-yl)dibenzothiophen-1-yl]acetamide) combined high potency against the target enzyme (DNA-PK IC50 = 8 nM) with promising activity as potentiators of ionizing radiation-induced cytotoxicity in vitro.

DNA-PK INHIBITORS

A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is -NH-C(=O)- or -O-; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is -O-, X is additionally selected from -C(=O)-NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R6 and R7 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is -NH-C(=O)-, -Y-X may additionally be selected from C1-7 alkyl.

DNA-PK INHIBITORS

Compounds of formula: (I) wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N; and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(=O), CH2 and NH are disclosed for use in inhibiting DNA-PK.

NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel tricyclic compounds useful for the treatment of inflammatory conditions, diseases of the central nervous and insulin resistant diabetes.

Rational Design of Templates for Intramolecular O,N-Acyl Transfer via Medium-Sized Cyclic Intermediates Derived from L-Cysteine. Definition of an Experimental Maximum in Effective Molarity through the Study of "Tunable" Templates

Rate constants and effective molarities for intramolecular O,N-acyl transfer have been measured for a series of unsymmetrical disulfides derived from cysteine and having the general structure H-Cys(S-XY-OAc)-OMe, for which XY is a rigid molecular spacing element that maintains a fixed OS distance lying in the range of 4.5-6.5 Angstroem.A synthetic route is described to 4-hydroxy-6-mercaptodibenzothiophene, involving lithiation of 4-methoxydibenzothiophene followed by reaction with elemental sulfur and positional isomer separation.A maximum effective molarity (EM) value of 5 M is seen for 4,6-disubstituted dibenzofuran function (OS = 5.45 Angstroem) while EM values of less than 0.1 M are seen for 4,6-disubstituted phenoxathiin and 4,6-disubstituted dibenzothiophene functions (OS = 3.90 and 6.30 Angstroem, respectively).Distance calculations and estimates of strain energy based on torsional and van der Waals terms are used to show that this result is consistent with a cyclic transition state containing one conformation of the cysteine framework.Energy minimization calculations were carried out by using a novel null-vector procedure for finding allowed torsional motions.They imply that the transition state for O,N-acyl transfer is strained by ca. 6 kcal/mol in the dibenzofuran case.